| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 690.1 | 609.3 |
| Profit before tax | 266.6 | 440.2 |
| Net income | 144.7 | 284.2 |
| EPS (diluted, $ a share) | $0.32 | $0.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -49.1% |
|---|---|
| Revenue, year on year | +13.3% |
| Operating margin | 59.5% |
10-Q filed with the SEC, NASDAQ: RPRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Royalty Pharma plc: key numbers
- Share price
- $68.53Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Royalty Pharma plc
All →Royalty Pharma Earnings Call: Key Takeaways
Royalty Pharma raised 2026 guidance for the third consecutive quarter, driven by 12% year-to-date royalty receipt growth and strong clinical success across its development-stage portfolio.
- Call
- Nov 4, 2026, 8:00 AM ET
Royalty Pharma Financial Results
Royalty Pharma reported 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026, driven by strong performance from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.50 billion to $3.55 billion. Management highlighted $1.9 billion in announced transactions year-to-date, including new royalties on Zoryve and Mimrylo.
- Term
- Q3 2026
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra.”
Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board
Royalty Pharma EVP, Research & Investments Marshall Urist Sells $236K of Stock
Marshall Urist, EVP, Research & Investments, sold 4,126 shares of Royalty Pharma plc at $57.10 a share, worth $236K in total on Oct 5, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $236K
- Shares
- 4,126
- Price
- $57.10
- Role
- EVP, Research & Investments
- Holding change
- -100.0%
- Trade date
- Oct 5, 2026
Royalty Pharma EVP, Research & Investments Marshall Urist Sells $239K of Stock
Marshall Urist, EVP, Research & Investments, sold 4,126 shares of Royalty Pharma plc at $57.88 a share, worth $239K in total on Sep 28, 2026. Shares held after the trade: 4,126 (-50.0%).
- Value
- $239K
- Shares
- 4,126
- Price
- $57.88
- Role
- EVP, Research & Investments
- Holding change
- -50.0%
- Trade date
- Sep 28, 2026
Royalty Pharma EVP & Chairman, Partnering Christopher Hite Sells $5.85M of Stock
Christopher Hite, EVP & Chairman, Partnering, sold 100,000 shares of Royalty Pharma plc at $58.51 to $58.93 a share (average $58.53) in 2 transactions, worth $5.85M in total on Sep 22, 2026. Shares held after the trade: 270,401 (-1.4%).
- Value
- $5.85M
- Shares
- 100,000
- Average price
- $58.53
- Role
- EVP & Chairman, Partnering
- Holding change
- -1.4%
- Trade date
- Sep 22, 2026